TTrialPathMatch Me to Trials
← Back to trials
RecruitingCIN 2/3HPV InfectionPre-Cancerous Dysplasia

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

Eligible age

25–100 yrs

Accepts

Women

Locations

4 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).

Sponsor: Frantz Viral Therapeutics, LLC

You may qualify if…

  • ✓ Adult females age ≥ 25 years
  • ✓ Capable of informed consent
  • ✓ Any HPV genotype detectable by DNA test/HPV genotyping
  • ✓ Colposcopically-directed, histologically confirmed tissue diagnosis of cervical high grade squamous intraepithelial lesions (CIN2, CIN3, or CIN2/3)
  • ✓ Women of childbearing potential agree to use birth control through week17 of the study.
  • ✓ Weight ≥ 50kg

You may not qualify if…

  • ✕ Pregnant and nursing women
  • ✕ Active autoimmune disease
  • ✕ Taking immunosuppressive medication
  • ✕ HIV seropositivity
  • ✕ Immunocompromised subjects
  • ✕ Evidence of concurrent cervical adenocarcinoma in situ
  • ✕ Concurrent malignancy except for nonmelanoma skin lesions, because treatment for other cancers have systemic effects

Where it's recruiting

Florida

Fort Myers

Michigan

Ann Arbor

Ohio

Cleveland · Mayfield Heights

Texas

Houston

Source: ClinicalTrials.gov · NCT04098744 · last updated 2025-10-02

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepitheli · TrialPath